Skip to main content
S&P 5007,673.52-0.58%DOW52,786.07-1.18%NASDAQ26,421.41-0.32%BTC$78,737.00-0.64%ETH$2,495.11+0.11%GOLD$4,398.60-0.91%OIL$94.62+1.71%
Smart Investors Daily
SR

NASDAQ · SRRK

Scholar Rock Holding Corporation

Healthcare · Biotechnology

$57.42

Up+$2.09 (+3.78%)

Updated Sep 9, 2026, 2:53 AM

SID Score

6.3/10

Composite research score

Smart Money

58/100

Neutral

Market cap
4.78B
P/E ratio
-15.08
Dividend yield
0.00%
52-week range
$27.07 – $61.76
Volume
1.84M
Avg. volume
2.6M

Price performance

SRRK price history

1M range · 20 trading sessions · Daily adjusted prices

SRRK closed at $57.42 after 20 trading sessions, up 10.27% for the selected period.

Last close
$57.42
Period change
+10.27%
Period low
$52.05
Period high
$60.04
Daily close
View OHLC price history
SRRK OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 8, 2026$54.088$57.79$54.00$57.421.84M
Sep 4, 2026$55.08$55.98$55.00$55.33658.05K
Sep 3, 2026$56.14$56.24$55.00$55.94803.49K
Sep 2, 2026$56.62$58.10$55.2701$56.101.07M
Sep 1, 2026$56.45$57.70$55.33$55.89763.19K
Aug 31, 2026$57.20$57.815$56.10$56.80987.26K
Aug 28, 2026$58.75$59.30$57.17$57.80809.72K
Aug 27, 2026$60.00$60.175$58.87$59.26620.74K
Aug 26, 2026$58.25$61.76$57.61$60.042.28M
Aug 25, 2026$58.20$59.48$57.06$58.251.21M
Aug 24, 2026$56.80$58.75$55.90$58.201.22M
Aug 21, 2026$55.38$57.10$54.98$56.501.16M
Aug 20, 2026$55.93$56.75$54.84$55.251.53M
Aug 19, 2026$56.13$57.15$54.09$56.511.33M
Aug 18, 2026$51.91$54.78$51.91$54.721.22M
Aug 17, 2026$52.00$52.97$51.82$52.05778.85K
Aug 14, 2026$52.94$52.965$51.50$52.52496.6K
Aug 13, 2026$54.84$55.00$52.68$53.06942.96K
Aug 12, 2026$52.18$54.70$51.85$53.82899.25K
Aug 11, 2026$52.12$53.125$51.2491$52.07853.9K

Latest SRRK news

The latest Smart Investors Daily articles mentioning SRRK.

Stock researchCompany · Overview

SRRK research

Overview

Company profile and research snapshot.

Company profile

Scholar Rock Holding Corp is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for treating serious diseases in which signaling by protein growth factors plays a fundamental role. Its pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The group operates and manages its business as a single segment to assess performance and make operating decisions.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$49.50
Implied upside
—
Analysts
—
SRRK recent ratings
DateFirmRatingTarget
Sep 8, 2026HC Wainwright & Co.Buy—
Aug 13, 2026JP MorganOverweight—
Aug 10, 2026WedbushOutperform—
Aug 10, 2026HC Wainwright & Co.Buy—
Aug 7, 2026CitigroupBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 2, 2026

Scholar Rock Receives FDA Fast Track Designation for Apitegromab Facioscapulohumeral Muscular Dystrophy (FSHD) Program as Participant Dosing Commences in Phase 2 FORGE Trial

CAMBRIDGE, Mass., September 02, 2026--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its world-leading platform in myostatin biology, today announced that the FDA has granted Fast Track and Orphan Drug designations to apitegromab for the treatment of people living with FSHD. In addition, the Company announced that participant dosing is underway in the Phase 2 FORGE

Yahoo · Aug 27, 2026

Scholar Rock to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass., August 27, 2026--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its world-leading platform in myostatin biology, today announced that management will participate in the following investor conferences:

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By